North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis

Description

List of Tables

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is expected to reach US$ 315.74 billion by 2028. It is estimated to register a CAGR of 13.1% from 2022 to 2028.

Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market

According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents both scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the North America have developed new technologies for treating rare diseases and developing groundbreaking therapies. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the North America biopharmaceuticals market expansion.

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of cancer, growing product introduction in the region, and technological advancements in biopharmaceuticals. The biopharmaceuticals industry is at a pivotal stage in medical research with tremendous potential to further revolutionize the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C. The rising burden of chronic diseases and increased investment in research and development activities in the US are driving the market in the region. The biopharmaceuticals industry makes important contributions to the US economy. The US leads the world in most R&D investment and innovation indices. As of 2020, biopharmaceutical companies in the United States have more than 3,400 drugs in clinical development, accounting for almost half of the estimated 8,000 drugs worldwide (of which 1,100 are being developed to treat various types of cancer). The biopharmaceuticals industry makes important contributions to the US economy by creating direct economic activities and supporting indirect activities. Pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added in 2018. Biotech R&D facilities accounted for another 0.23%. Data from the Centers for Disease Control and Prevention (CDC), updated in July 2022, shows that coronary artery disease is the most common form of heart disease. Approximately 20.1 million adults aged 20 and older in the United States suffer from this condition. According to CDC data, someone suffers a heart attack every 40 seconds, and nearly 805,000 people in the US suffer a heart attack annually. All these factors are expected to boost the North America biopharmaceuticals market growth significantly during the forecast period.

North America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

North America Biopharmaceuticals Market Segmentation

The North America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the North America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the North America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the North America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the North America biopharmaceuticals market.

Based on country, the North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. In 2022, the US accounted for the largest share of the North America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading companies operating in the North America biopharmaceuticals market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America biopharmaceutical market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00028630

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Biopharmaceuticals Market - by Product Type
- 1.3.2 North America Biopharmaceuticals Market - by Application
- 1.3.3 North America Biopharmaceuticals Market - by Country

2. North America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Biopharmaceuticals Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Expert's Opinion

5. North America Biopharmaceuticals Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Application in Cancer Therapeutics
- 5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
- 5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
- 5.3.1 Accelerated Clinical Trials
5.4 Future Trends
- 5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis

6. Biopharmaceuticals Market - North America Analysis

6.1 North America Biopharmaceuticals Market Revenue Forecast and Analysis

7. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
- 7.3.1 Overview
- 7.3.2 Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
- 7.4.1 Overview
- 7.4.2 Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 Cancer Vaccine
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.2 Malaria Vaccine
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.3 Ebola Vaccine
    - 7.4.2.3.1 Overview
    - 7.4.2.3.2 Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.4 Hepatitis-B Vaccine
    - 7.4.2.4.1 Overview
    - 7.4.2.4.2 Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.5 Tetanus Vaccine
    - 7.4.2.5.1 Overview
    - 7.4.2.5.2 Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.6 Diphtheria Vaccine
    - 7.4.2.6.1 Overview
    - 7.4.2.6.2 Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.7 Cholera Vaccine
    - 7.4.2.7.1 Overview
    - 7.4.2.7.2 Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.8 Others
    - 7.4.2.8.1 Overview
    - 7.4.2.8.2 Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
- 7.5.1 Overview
- 7.5.2 Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 Polio Vaccine
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.2 Pox Vaccine
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.3 Other Conventional Vaccine
    - 7.5.2.3.1 Overview
    - 7.5.2.3.2 Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
- 7.6.1 Overview
- 7.6.2 Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 Erythropoietin
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.2 Granulocyte Colony Stimulating Factor
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
- 7.7.1 Overview
- 7.7.2 Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.1 Leukemia Inhibitory Factor (LIF)
    - 7.7.2.1.1 Overview
    - 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.2 P53 Protein
    - 7.7.2.2.1 Overview
    - 7.7.2.2.2 P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.3 P38 Protein
    - 7.7.2.3.1 Overview
    - 7.7.2.3.2 P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.4 Other Purified Proteins
    - 7.7.2.4.1 Overview
    - 7.7.2.4.2 Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
- 7.8.1 Overview
- 7.8.2 Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.1 Serum Albumin
    - 7.8.2.1.1 Overview
    - 7.8.2.1.2 Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.2 Amyloid Protein
    - 7.8.2.2.1 Overview
    - 7.8.2.2.2 Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.3 Defensin
    - 7.8.2.3.1 Overview
    - 7.8.2.3.2 Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.4 Transferrin
    - 7.8.2.4.1 Overview
    - 7.8.2.4.2 Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
- 7.9.1 Overview
- 7.9.2 Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.1 Recombinant Human Growth Hormones
    - 7.9.2.1.1 Overview
    - 7.9.2.1.2 Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.2 Recombinant Insulin
    - 7.9.2.2.1 Overview
    - 7.9.2.2.2 Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.3 Other Recombinant Hormones
    - 7.9.2.3.1 Overview
    - 7.9.2.3.2 Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
- 7.10.1 Overview
- 7.10.2 Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.1 Enterokinase
    - 7.10.2.1.1 Overview
    - 7.10.2.1.2 Enterokinase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.2 Cyclase
    - 7.10.2.2.1 Overview
    - 7.10.2.2.2 Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.3 Caspase
    - 7.10.2.3.1 Overview
    - 7.10.2.3.2 Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.4 Cathepsin
    - 7.10.2.4.1 Overview
    - 7.10.2.4.2 Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
- 7.11.1 Overview
- 7.11.2 Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.1 Allogenic Products
    - 7.11.2.1.1 Overview
    - 7.11.2.1.2 Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.2 Autologous Products
    - 7.11.2.2.1 Overview
    - 7.11.2.2.2 Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.3 Acellular Products
    - 7.11.2.3.1 Overview
    - 7.11.2.3.2 Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
- 7.12.1 Overview
- 7.12.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
- 7.13.1 Overview
- 7.13.2 Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

8.1 Overview
8.2 North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
- 8.3.1 Overview
- 8.3.2 Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
- 8.4.1 Overview
- 8.4.2 Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
- 8.5.1 Overview
- 8.5.2 Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
- 8.7.1 Overview
- 8.7.2 Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
- 8.8.1 Overview
- 8.8.2 Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
- 8.9.1 Overview
- 8.9.2 Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
- 8.10.1 Overview
- 8.10.2 Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

9.1 Overview
- 9.1.1 North America: Biopharmaceuticals Market, by Country
  - 9.1.1.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.1.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.1.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.1.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.1.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.1.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.1.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.1.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.1.1.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.1.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.1.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.1.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.1.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.1.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.1.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.1.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.1.1.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.1.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.1.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.1.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.1.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.1.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.1.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.1.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.1.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. North America Biopharmaceuticals Market - Industry Landscape

10.1 Overview
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview

11. Company Profiles

11.1 Amgen Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Eli Lilly and Co
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Johnson & Johnson
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Boehringer Ingelheim International GmbH
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Thermo Fisher Scientific Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 AGC Biologics AS
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Lonza Group AG
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 WuXi Biologics Inc
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms